DK4034555T3 - Dap10/dap12-fusionspolypeptider - Google Patents

Dap10/dap12-fusionspolypeptider Download PDF

Info

Publication number
DK4034555T3
DK4034555T3 DK20788997.3T DK20788997T DK4034555T3 DK 4034555 T3 DK4034555 T3 DK 4034555T3 DK 20788997 T DK20788997 T DK 20788997T DK 4034555 T3 DK4034555 T3 DK 4034555T3
Authority
DK
Denmark
Prior art keywords
dap10
fusion polypeptides
dap12
dap12 fusion
polypeptides
Prior art date
Application number
DK20788997.3T
Other languages
English (en)
Inventor
John Maher
David Marc Davies
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Application granted granted Critical
Publication of DK4034555T3 publication Critical patent/DK4034555T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK20788997.3T 2019-09-23 2020-09-23 Dap10/dap12-fusionspolypeptider DK4034555T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201913697A GB201913697D0 (en) 2019-09-23 2019-09-23 DAP10/DAP12 fusion polypeptides
PCT/EP2020/076566 WO2021058563A1 (en) 2019-09-23 2020-09-23 Dap10/dap12 fusion polypeptides

Publications (1)

Publication Number Publication Date
DK4034555T3 true DK4034555T3 (da) 2025-03-24

Family

ID=68425491

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20788997.3T DK4034555T3 (da) 2019-09-23 2020-09-23 Dap10/dap12-fusionspolypeptider

Country Status (15)

Country Link
US (1) US20220332788A1 (da)
EP (2) EP4034555B1 (da)
JP (2) JP2022550485A (da)
KR (1) KR20220069025A (da)
CN (1) CN114729027A (da)
AU (2) AU2020352574B2 (da)
BR (1) BR112022005426A2 (da)
CA (1) CA3155168A1 (da)
DK (1) DK4034555T3 (da)
ES (1) ES3015617T3 (da)
FI (1) FI4034555T3 (da)
GB (1) GB201913697D0 (da)
IL (1) IL291493A (da)
MX (2) MX2022003531A (da)
WO (1) WO2021058563A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024541081A (ja) 2021-11-15 2024-11-06 ネオジン セラピューティクス ビー．ブイ． 低下したｔｇｆ－ベータ受容体シグナル伝達を有する遺伝子操作されたｔ細胞
GB202214120D0 (en) * 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
WO2024209084A1 (en) 2023-04-05 2024-10-10 Kings College London Parallel chimeric antigen receptors (pcars) and adaptor chimeric antigen receptors comprising alternative signalling domains and methods of use thereof
WO2025140265A1 (en) * 2023-12-26 2025-07-03 Wuxi Biologics (Shanghai) Co., Ltd. Combination of chimeric antigen receptor and dap10 in cell therapy
GB202403718D0 (en) 2024-03-14 2024-05-01 King S College London Therapeutic agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CN113862292B (zh) * 2015-01-29 2024-12-27 明尼苏达大学董事会 嵌合抗原受体、组合物以及方法
WO2016172583A1 (en) * 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP7198670B2 (ja) * 2016-04-20 2023-01-04 フレッド ハッチンソン キャンサー センター 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
CN117363636A (zh) * 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
EP3697809A1 (en) * 2017-10-20 2020-08-26 Institut Curie Dap10/12 based cars adapted for rush
WO2019182425A1 (ko) 2018-03-23 2019-09-26 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
EP3848387A4 (en) * 2018-09-05 2022-06-22 Kong, Seogkyoung CHIMERIC ANTIGEN RECEPTOR FOR SOLID TUMOR AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途
SG11202108655TA (en) * 2019-02-15 2021-09-29 Univ Southern California Lym-1 and lym-2 antibody compositions and improved car constructs
GB202007655D0 (en) * 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
BR112023019385A2 (pt) * 2021-03-23 2023-12-05 King S College London Composições compreendendo polipeptídeos de fusão nkg2d, cxcr2 e dap10/dap12 e seus métodos de uso

Also Published As

Publication number Publication date
US20220332788A1 (en) 2022-10-20
EP4566622A3 (en) 2025-08-20
AU2020352574B2 (en) 2025-12-18
WO2021058563A1 (en) 2021-04-01
MX2022003531A (es) 2022-07-11
CN114729027A (zh) 2022-07-08
EP4034555B1 (en) 2025-02-12
FI4034555T3 (fi) 2025-03-17
EP4034555A1 (en) 2022-08-03
MX2025010859A (es) 2025-10-01
EP4566622A2 (en) 2025-06-11
AU2026201858A1 (en) 2026-04-02
IL291493A (en) 2022-05-01
JP2025108507A (ja) 2025-07-23
GB201913697D0 (en) 2019-11-06
CA3155168A1 (en) 2021-04-01
AU2020352574A1 (en) 2022-04-21
KR20220069025A (ko) 2022-05-26
ES3015617T3 (en) 2025-05-06
JP2022550485A (ja) 2022-12-01
BR112022005426A2 (pt) 2022-06-21

Similar Documents

Publication Publication Date Title
IL288479A (en) Glucagon-like peptide 1 receptor agonists
IL281954A (en) Heterodimeric fc-fused proteins
EP3880814A4 (en) FUSION PROTEIN
IL282462A (en) Control search space overlap indication
IL291493A (en) dap10/dap12 fusion polypeptides
LT3762380T (lt) Fenilpirolidinono formilpeptido 2 receptoriaus antagonistai
EP3849598A4 (en) ANTI-TREM-2 AGONIST ANTIBODIES
IL285909A (en) Anti-bcma chimeric antigen receptors
IL276836A (en) Cd83-binding chimeric antigen receptors
EP3806903A4 (en) CD79A CHIMERIC ANTIGEN RECEPTORS
EP3802565A4 (en) POLYPEPTIDES
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
EP4078942C0 (en) FUSION OF IMAGES
IL290878A (en) Protein based cannabis compositions
EP3768720A4 (en) NEW ANTI-BODY ANTI-LAG-3 POLYPEPTIDE
EP3634466A4 (en) MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS
PL3613739T3 (pl) Antagoniści integryn
EP4317184A4 (en) BISPECIFIC MULTIFUNCTIONAL FUSION POLYPEPTIDE
MA53493A (fr) Polypeptides leurres
EP4257597A4 (en) LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
HUE065269T2 (hu) Peptidek
EP3830105A4 (en) CHIMERA IMMUNOGENIC POLYPEPTIDES
EP3919773C0 (en) LIQUID-FILLED COMPOSITE SPRING
EP3740501A4 (en) FUSION PROTEIN EXTENSIONS
DK3774879T3 (da) C-terminale antistofvarianter